## Pharmacoeconomics Workshop 2020-2021

A Workshop is a class exercise based on group work. Students will be given a number of tasks alongside some reading materials. You will be asked to work through them with your group and this would be followed by feedback and class discussion.

There will be no marks assigned to your work, however this would be highly advised to help you master the skills required for the midterm and final exams.

You will be allowed to use the lecture notes, text books or your own notes and a calculator.

## Learning outcomes

By the end of the workshop you will be able to:

- Critically read an economic paper
- Practice further


## Process

- Workshop introduction (5 minutes)
- In groups of 4-5 students; start to work through the worksheet of this workshop papers (40 minutes)
- During the workshop Dr. Rimal will be available to advice and facilitate group discussions, please raise your hand and she will call up to your group.
- Submit work with 30 minutes


## Exercise 1: Decision tree

You are a hospital manger and looking to compare two drugs: A and B for the treatment of UTI to decide which to purchase in the formulary. Please review Table 1summarizing outcomes and probability

Table 1

| Outcome and probability | Drug A | Drug B |
| :--- | :--- | :--- |
| Effectiveness probability | 0.95 | 0.85 |
| Side effect probability | 0.05 | 0.15 |
| Cost of medication separately | $\$ 120$ | $\$ 100$ |
| Cost of side effects separately | $\$ 50$ | $\$ 50$ |
| Utility of medication without side effects | 0.9 | 0.7 |
| Utility of medications with side effects | 0.5 | 0.6 |
| Life year gained of medication without side effects 6 | 5 |  |
| Life year gained of medications and side effects | 6 | 5 |

Please help to complete the following decision tree (estimated working time 20 min )


No side effects

Hint: use the calculation for Drug A as a guide to perform calculation to Drug B

|  | Cost | Probability | Probability $\times$ Cost $(\$)$ |
| :--- | :--- | :--- | :--- |
| Drug $\mathbf{A}$ |  |  |  |
| Outcome 1 | $\$ 120+\$ 50=\$ 170$ | $0.95 \times 0.05=0.0475$ | 8.08 |
| Outcome 2 | $\$ 120$ | $0.95 \times 0.95=0.9025$ | 108.30 |
| Outcome 3 | $\$ 120+\$ 50=\$ 170$ | $0.05 \times 0.05=0.0025$ | 0.42 |
| Outcome 4 | $\$ 120$ | $0.05 \times 0.95=0.0475$ | 5.70 |
| Total |  | 1 | $\mathbf{1 2 2 . 5}$ |

Drug B calculation

| Drug B | Cost | Probability | Probability $\times$ Cost (\$) |
| :--- | :--- | :--- | :--- |
| Outcome 1 |  |  |  |
| Outcome 2 |  |  |  |
| Outcome 3 |  |  |  |
| Outcome 4 |  |  |  |
| Total |  |  |  |

Calculate ICUR using the above two table

## Exercise 2: Markov Model

The following is the basic structure of the model which evaluated the use of combination therapy (Lamivudine and AZT) for two years against monotherapy (AZT alone)


The cycle length is one year and it is evaluated for 5 years
Use the data given below to populate the model and calculate the incremental cost-effectiveness ratio for monotherapy

## Transition probabilities

They were calculated from the counts of individuals that were observed to move between four health states each year. These counts were as the following.

|  | A | B | C | D | Total |
| :--- | :--- | :--- | :--- | :--- | :--- |
| A | 1251 | 350 | 116 | 17 | 1734 |
| B | 0 | 731 | 512 | 15 | 1258 |
| C | 0 | 0 | 1312 | 437 | 1749 |

Calculate the transition probabilities from each state

|  | A | B | C | D |
| :--- | :--- | :--- | :--- | :--- |
| A | $=1251 / 1734$ |  |  |  |
| B |  |  |  |  |

## State costs <br> The costs for each state were reported as the following for Monotherapy

| Costs | A | B | C |
| :--- | :--- | :--- | :--- |
| Direct medical cost | 3,979 | 4,052 | 9,226 |

## Discounting

Consider yearly discounting of $3.5 \%$ for both costs and outcomes

Filling the following tables will help you to estimate the cost-effectiveness ratio

1. First, calculate the possible transition to each state within each cycle (example in the first cycle)
2. Second, calculate the LYG for each year and then discounted yearly using the discounting formula $=$ undiscounted benefit/ $(1+r)^{\wedge} t$ where $t$ the number of cycle; $r$ equals to the discount rate
3. Third, calculate the cost for each year and then discounted yearly
4. Fourth, sum the discounted LYG and cost across all the cycles for each therapy
5. Calculate the ICER


